COMMUNIQUÉS West-GlobeNewswire

-
Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
08/03/2024 -
SciSparc Announces Enrollment of First Patient for its Clinical Trial for Children with Autism Spectrum Disorder
08/03/2024 -
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet
08/03/2024 -
Bio-Path Holdings Reports Full Year 2023 Financial Results
08/03/2024 -
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
08/03/2024 -
Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
08/03/2024 -
As part of International Women’s Day 2024, Women’s Health Advocate calls on expeditious passage of C-64: An Act Respecting Pharmacare
08/03/2024 -
Dans le cadre de la Journée internationale des femmes de 2024, les professionnels de la santé des femmes demandent à ce que le projet de loi C-64, Loi concernant l’assurance médicaments, soit adopté rapidement
08/03/2024 -
Augmedix to Announce Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
08/03/2024 -
Galimedix Therapeutics presents new scientific data showing promising neuroprotective effects of GAL-201 for the treatment of Alzheimer’s disease at AD/PD™ 2024
08/03/2024 -
Crossject gender equality score reaches 96/100 in 2024
08/03/2024 -
Le Score de l’index Egalité femmes-hommes chez Crossject atteint 96/100 en 2024
08/03/2024 -
Hyloris to Report 2023 Full-Year Results on 14 March 2024
08/03/2024 -
Hyloris Annonce ses Résultats Financiers Annuels le 14 mars 2024
08/03/2024 -
Mithra reports full year 2023 financial results
08/03/2024 -
Scorpius Holdings, Inc. Announces Pricing of Public Offering
08/03/2024 -
RadNet Announces Pricing of Public Offering of Common Stock
08/03/2024 -
Extendicare Announces 2023 Fourth Quarter and Year End Results
08/03/2024 -
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
08/03/2024
Pages